ArticleEuropean urology focus2016

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Tamara L Lotan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.